JP2022551185A5 - - Google Patents

Info

Publication number
JP2022551185A5
JP2022551185A5 JP2022521718A JP2022521718A JP2022551185A5 JP 2022551185 A5 JP2022551185 A5 JP 2022551185A5 JP 2022521718 A JP2022521718 A JP 2022521718A JP 2022521718 A JP2022521718 A JP 2022521718A JP 2022551185 A5 JP2022551185 A5 JP 2022551185A5
Authority
JP
Japan
Prior art keywords
alkyl
membered heterocycloalkyl
branched
pharmaceutically acceptable
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551185A (ja
JP7724394B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/078483 external-priority patent/WO2021069705A1/en
Publication of JP2022551185A publication Critical patent/JP2022551185A/ja
Publication of JP2022551185A5 publication Critical patent/JP2022551185A5/ja
Application granted granted Critical
Publication of JP7724394B2 publication Critical patent/JP7724394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521718A 2019-10-09 2020-10-09 イソインドリノン化合物 Active JP7724394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH12812019 2019-10-09
CH01281/19 2019-10-09
PCT/EP2020/078483 WO2021069705A1 (en) 2019-10-09 2020-10-09 Isoindolinone compounds

Publications (3)

Publication Number Publication Date
JP2022551185A JP2022551185A (ja) 2022-12-07
JP2022551185A5 true JP2022551185A5 (https=) 2023-10-17
JP7724394B2 JP7724394B2 (ja) 2025-08-18

Family

ID=68242216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521718A Active JP7724394B2 (ja) 2019-10-09 2020-10-09 イソインドリノン化合物

Country Status (4)

Country Link
US (1) US20220242846A1 (https=)
EP (1) EP4041231A1 (https=)
JP (1) JP7724394B2 (https=)
WO (1) WO2021069705A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021126973A1 (en) * 2019-12-17 2021-06-24 Orionis Biosciences, Inc. Compounds modulating protein recruitment and/or degradation
JP2023545274A (ja) * 2020-10-07 2023-10-27 クルゲン（シャンハイ），インク． 癌を処置する化合物および方法
US20240085421A1 (en) 2021-01-13 2024-03-14 Monte Rosa Therapeutics, Inc. Methods for the identification of degrons
US20240261274A1 (en) 2021-01-13 2024-08-08 Monte Rosa Therapeutics, Inc. Treatment of myc-driven cancers with gspt1 degraders
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
CN117242060A (zh) * 2021-01-13 2023-12-15 蒙特罗萨医疗公司 异吲哚啉酮化合物
WO2022200857A1 (en) * 2021-03-22 2022-09-29 Monte Rosa Therapeutics Ag Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
WO2022256623A1 (en) 2021-06-04 2022-12-08 Monte Rosa Therapeutics, Inc. E3 ligase fusion proteins for proximity detection
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
JP2024527628A (ja) * 2021-07-19 2024-07-25 メッドシャイン ディスカバリー インコーポレイテッド ヘテロアリール－３－ピペリジンジオン化合物その使用
WO2023069700A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023069720A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023069708A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and uses thereof
WO2023091567A1 (en) 2021-11-17 2023-05-25 Monte Rosa Therapeutics, Inc. Degron and neosubstrate identification
CA3255290A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company NEW GSPT1 COMPOUNDS AND METHODS FOR USING THE NEW COMPOUNDS
WO2024015855A1 (en) 2022-07-13 2024-01-18 Monte Rosa Therapeutics, Inc. COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS
EP4554935A1 (en) * 2022-07-14 2025-05-21 Monte Rosa Therapeutics AG Methods of preparing an isoindolinone derivative and crystal forms thereof
WO2024027795A1 (zh) * 2022-08-04 2024-02-08 苏州开拓药业股份有限公司 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
EP4584259A1 (en) 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
KR20260005248A (ko) * 2023-03-24 2026-01-09 주식회사 핀테라퓨틱스 Gspt1 분해 화합물 및 분해 방법
CN121311477A (zh) * 2023-09-06 2026-01-09 上海超阳药业有限公司 内酰胺类衍生物及其应用
WO2025085416A1 (en) * 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025146112A1 (en) * 2024-01-05 2025-07-10 Primelink Biotherapeutics (Shenzhen) Co., Ltd. Gspt1 degrading compounds and compositions and uses thereof
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025259615A1 (en) * 2024-06-11 2025-12-18 Triana Biomedicines, Inc. Modulators of cdk2 and uses thereof
WO2026007898A1 (zh) * 2024-07-01 2026-01-08 上海海雁医药科技有限公司 含苯乙氧基亚烷基胺结构的异吲哚啉化合物、其药物组合物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
CL2007002513A1 (es) * 2006-08-30 2008-04-04 Celgene Corp Soc Organizada Ba Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
PT2358697E (pt) * 2008-10-29 2016-02-03 Celgene Corp Compostos de isoindolina para utilização no tratamento do cancro
AR108222A1 (es) * 2016-05-05 2018-08-01 Elanco Tiergesundheit Ag Compuestos heteroaril-1,2,4-triazol y heteroaril-tetrazol
CN109790143A (zh) * 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
WO2019148055A1 (en) * 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
BR112022019532A2 (pt) * 2020-03-31 2022-12-06 Orum Therapeutics Inc Conjugados de neodegrader

Similar Documents

Publication Publication Date Title
JP2022551185A5 (https=)
JP2022510313A5 (https=)
JP2023553835A5 (https=)
JP2012505871A5 (https=)
JP2020169171A5 (https=)
JP2022539089A5 (https=)
JP2010506854A5 (https=)
JP2021514001A5 (https=)
JP2007501859A5 (https=)
JP2013542223A5 (https=)
JP2011509309A5 (https=)
JP2013502431A5 (https=)
JP2009536660A5 (https=)
JP2011520815A5 (https=)
JP2019518766A5 (https=)
JP2010138190A5 (https=)
RU2011127079A (ru) Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с
JP2014527974A5 (https=)
RU2017121906A (ru) Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии
JP2010514786A5 (https=)
RU2010133903A (ru) Способ и промежуточные соединения для получения производных 5-бифенил-4-ил-2-метилпентановой кислоты
JP2016518434A5 (https=)
JP2022522694A5 (https=)
RU2016108987A (ru) Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
JP2024541910A5 (https=)